Humanetics’ BIO 300 Shows Promise in Preventing Radiation-induced ED and Tumor Growth in Prostate Cancer

Humanetics’ BIO 300 Shows Promise in Preventing Radiation-induced ED and Tumor Growth in Prostate Cancer
A recent study using animals demonstrated that Humanetics' BIO 300 reduces radiation-induced erectile dysfunction and slows tumor growth. Radiation-induced erectile dysfunction is a common side effect observed in more than half of men treated with radiation therapy for prostate cancer. There currently are no FDA-approved drugs to mitigate radiation-induced erectile dysfunction. BIO 300 (nano-genistein) has been developed by Humanetics Corporation to reduce radiation-associated toxicities in multiple cancers. It already is being studied in Phase 1b/2a clinical trials in patients with non-small cell lung cancer receiving chemoradiotherapy.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *